Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor ISM3312 for COVID-19 New York, Feb. 23, 2023 (GLOBE NEWSWIRE) -- ISM3312 is a highly selective 3CLpro inhibitor with a novel molecular structure optimized from compounds designed by Chemistry42, Insilico’s...

Insilico Medicine Opens Largest AI-Powered Biotechnology Research Center in the Middle East Abu Dhabi, Feb. 01, 2023 (GLOBE NEWSWIRE) -- Insilico Medicine ("Insilico"), a clinical-stage artificial intelligence (AI)-driven drug discovery company, is announcing today the opening of the...

Insilico Medicine to Present at 41st Annual J.P. Morgan Healthcare Meeting New York, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine will present at the  41st Annual J.P. Morgan Healthcare Meeting happening Jan. 9-12, 2023 at the Westin St. Francis Hotel in San...

Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion Abu Dhabi, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research...

Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion New York, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Insilico Medicine, a clinical stage artificial intelligence (AI)-driven drug discovery company, announced a multi-year, multi-target strategic research...